Table 2.
Routine laboratory and clinical findings at study entry
| IgAN | IgAV adults | IgAV pediatrics | P value IgAV adults, IgAN | P value IgAV adults, pediatrics | Overall P value | |
|---|---|---|---|---|---|---|
| N | 45 | 60 | 60 | |||
| Clinical presentation | ||||||
| Palpable purpura | 0/44 (0.0%) | 60 (100.0%) | 60 (100.0%) | N/A | N/A | N/A |
| Arthralgia | 0/44 (0.0%) | 6 (10.0%) | 27 (45.0%) | .001 | .001 | .001 |
| Arthritis | 0/44 (0.0%) | 12 (20.0%) | 41 (68.3%) | .002 | .001 | .001 |
| Abdominal pain | 4/35 (11.4%) | 21 (35.0%) | 31 (51.7%) | .01 | .06 | .001 |
| Hematochezia | 0/44 (0.0%) | 2 (3.3%) | 5 (8.3%) | .51 | .44 | .10 |
| Intussusception | 1/44 (2.3%) | 0 (0.0%) | 2 (3.3%) | .42 | .50 | .38 |
| Renal involvement | ||||||
| Serum creatinine (mg/dL) | 1.924 ± 1.717 (0.63–10.20) |
1.144 ± 1.141 (0.50–6.93) |
0.418 ± 0.13759 (0.19–0.72) |
.001 | .001 | .001 |
| Hematuria | 38/44 (86.4%) | 21/49 (42.9%) | 8 (13.6%) | .001 | .001 | .001 |
| Leukocyturia | 4/44 (9.1%) | 13/49 (26.5%) | 9/59 (15.3%) | .03 | .15 | .07 |
| Dipstick proteinuria | 40 (88.9%) | 21/49 (42.9%) | 20/59 (33.9%) | .001 | .34 | .001 |
| Proteinuria > 300 (mg/day) or Urine P/C > 300 (mg/g) | 40/42 (95.2%) | 23/38 (60.5%) | 13/31 (41.1%) | <.001 | .13 | <.001 |
| Proteinuria (mg/24h) | 2609.0 ± 1854.536 (249–7522.8) |
1303.06 ± 2486.8629 (57.2–10,648.2) |
1654.98 ± 3281.2115 (30–11,600.0) |
.001 | .25 | .001 |
| Urine P/C (mg/g) | 2224.6 ± 1661.332 (151.4–5662.3) |
1123.76 ± 1758.6229 (36–7889.6) |
2812.10 ± 8807.4519 (105.5–39,000) |
.001 | .22 | .001 |
| Laboratory studies | ||||||
| C-reactive protein (mg/dL) | 2.66 ± 4.64 24 (0.05–17.30) |
5.84 ± 6.32 57 (0.25–26.30) |
3.39 ± 2.46 43 (0.15–9.59) |
.001 | .09 | .001 |
| IgA > 300 mg/dL | (78.6%) 11/14 460.21 ± 240.16 |
19/30 (63.3%) 373.60 ± 160.54 |
2/8 (25%) 221.13 ± 91.54 |
.30 | .05 | .05 |
| IgG (mg/dL) | 988 ± 189.99 17 (669–1282) |
1273.69 ± 547.68 29 (302–2336) |
1029.71 ± 253.86 7 (607–1336) |
.02 | .26 | .08 |
| IgM (mg/dL) | 98.19 ± 48.33 16 (27–214) |
108.66 ± 83.08 28 (24–420) |
95.81 ± 41.94 7 (46–169) |
.65 | .70 | .84 |
| C3 (mg/dL) | 116.60 ± 19.84 29 (69.3–154.7) |
134.22 ± 36.05 41 (37–198.3) |
148.32 ± 24.52 16 (110–199) |
.05 | .16 | .002 |
| C4 (mg/dL) | 35.52 ± 11.36 29 (13.5–64.4) |
28.66 ± 11.84 40 (3.0–51.8) |
31.80 ± 9.14 16 (19.0–54.0) |
.04 | .35 | .10 |
| ANA Titers | ||||||
| 1:80 | 0/34 (0.0%) | 0/47 (0.0%) | 5/13 (38.5%) | .50 | .001 | .001 |
| 1:160 | 2/34 (5.9%) | 3/47 (6.3%) | 0 (0.0%) | |||
| 1:320 | 1/34 (2.9%) | 0/47 (0.0%) | 0 (0.0%) | |||
| ENA positive | 4/30 (13.3%) | 3/39 (7.7%) | 0/9 (0.0%) | .44 | >.99 | .44 |
| Initial treatment | ||||||
| NSAID | 0 (0.0%) | 6/53 (11.3%) | 35 (58.3%) | .03 | <.001 | .001 |
| Prednisone | 14 (31.1%) | 26/55 (47.3%) | 41 (68.3%) | .10 | .02 | .001 |
| IV pulse steroids | 6 (13.3%) | 7/54 (13.0%) | 13 (21.7%) | .96 | .22 | .37 |
| ACEi/ARB | 28 (62.2%) | 21/55 (38.2%) | 2 (3.3%) | .02 | <.001 | .001 |
| Cyclophosphamide | 0 (0.0%) | 1/54 (1.9%) | 0 (0.0%) | >.99 | .47 | .38 |
| Cyclosporine | 0 (0.0%) | 1/54 (1.9%) | 1 (1.7%) | >.99 | >.99 | .67 |
| Imuran | 0 (0.0%) | 1/55 (1.8%) | 0 (0.0%) | >.99 | .48 | .38 |
| Dermatologic topical drug | 0 (0.0%) | 18/55 (32.7%) | 3 (5.0%) | <.001 | <.001 | .001 |
| Colchicine | 0 (0.0%) | 7/52 (13.5%) | 0 (0.0%) | .36 | .003 | .001 |
| Dialysis | 3 (6.8%) | 7/55 (12.7%) | 0 (0.0%) | .50 | .005 | .02 |
Bold values represents significant P-values. Superscript numbers are number of patients with available information.
ACEi = angiotensin-converting enzyme inhibitor, ARB = angiotensin II receptor blocker, IgAN = IgA nephropathy, IgAV = IgA vasculitis, IV = intravenous, N = number of patients, N/A = not available, NSAID = non-steroidal anti-inflammatory drug, Urine P/C = urine protein to urine creatinine ratio.